Tel Aviv, Israel / Vancouver, Canada, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will participate in a special virtual event to discuss the current psychedelic renaissance that is opening the doors to the benefits of both traditional and novel psychedelics, as older therapies are being re-examined and new molecules are being identified for current and future clinical studies.
The virtual event will be held on Wednesday, Nov 29, 2023 at 12pm EST/ 9am PST. Register here.
The virtual event is part of The Psychedelic Association of Canada (PAC) "Industry Presents" Series. The host for the event is Gillian Maxwell, a PAC Board Member, that was a part of Canada’s harm reduction and drug policy reform. She co-founded the Canadian Drug Policy Coalition (CDPC) and served on the board of directors of MAPS Canada for over 10 years.
The main guest for the virtual event will be Rick Doblin, PhD, an American drug activist and executive who is the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines.
Clearmind's CEO, Adi Zuloff-Shani, PhD, will share her thoughts about the Company's innovative MEAI molecule, defined as novel psychedelics. Mark Haden, MSW, VP of business development for Clearmind Medicine, will take part in the event as well.
For additional information and registration, please click here.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of fifteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: (604) 260-1566
US: This email address is being protected from spambots. You need JavaScript enabled to view it.
General Inquiries
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.Clearmindmedicine.com
| Last Trade: | US$1.86 |
| Daily Change: | -0.09 -4.62 |
| Daily Volume: | 50,493 |
| Market Cap: | US$2.790M |
December 16, 2025 December 12, 2025 December 02, 2025 December 01, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
